cancer-immunotherapy

Documents about cancer-immunotherapy

• A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer#467568ClinicalTrials.gov
• Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot#478495Europe PMC
• The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial#481752ClinicalTrials.gov
• Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy#668811ClinicalTrials.gov
• Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC#834480ClinicalTrials.gov
• Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers#831769ClinicalTrials.gov
• Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC#857850ClinicalTrials.gov
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure#136302ClinicalTrials.gov
• SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects#474781ClinicalTrials.gov
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations#256870ClinicalTrials.gov
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies#353286ClinicalTrials.gov
• Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy#146472ClinicalTrials.gov
• Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC#148772ClinicalTrials.gov
• The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer#268027ClinicalTrials.gov
• Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)#272352ClinicalTrials.gov
• A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis#329533ClinicalTrials.gov
• The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer#363606ClinicalTrials.gov
• A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer#806481ClinicalTrials.gov
• Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer#836209ClinicalTrials.gov
• Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma#836922ClinicalTrials.gov
• DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer#837696ClinicalTrials.gov
• Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC#858150ClinicalTrials.gov
• Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer#160375ClinicalTrials.gov
• A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer#411378ClinicalTrials.gov
• Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy#460089ClinicalTrials.gov
• SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia#18620ClinicalTrials.gov
• Rethinking EPO: A Paradigm Shift in Oncology?#137348HAL (France)
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma#152405ClinicalTrials.gov
• CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy.#154434NCBI PubMed Central
• Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy#160336ClinicalTrials.gov
• Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients#172324ClinicalTrials.gov
• pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy.#174565NCBI PubMed Central
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer#174862ClinicalTrials.gov
• Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage Cancer#174863ClinicalTrials.gov
• Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction#184871ClinicalTrials.gov
• Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.#185953NCBI PubMed Central
• Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC#201784ClinicalTrials.gov
• mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC#238125ClinicalTrials.gov
• A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer#256866ClinicalTrials.gov
• Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)#283060ClinicalTrials.gov
• Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours.#285035NCBI PubMed Central
• Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)#300262ClinicalTrials.gov
• The CSF1(+) tumor cell-SPP1(+) macrophage axis drives gastric cancer progression and immunotherapy resistance.#330849NCBI PubMed Central
• Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC#353285ClinicalTrials.gov
• Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge#366582ClinicalTrials.gov
• Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer#370802HAL (France)
• Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects#377410ClinicalTrials.gov
• Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy#377429ClinicalTrials.gov
• A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors#414483ClinicalTrials.gov
• Bladderpreservationalternativesin non-metastaticmuscle-invasivebladder tumor:Asystematicreviewand meta-analysis#434749Repositorio Universidad del Desarrollo